Multicenter Study to Evaluate the Efficacy and Safety of Oral ACT-539313 in the Treatment of Adults With Moderate to Severe Binge Eating Disorder

NCT04753164 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

136

Enrollment

INDUSTRY

Sponsor class

Conditions

Binge-Eating Disorder

Interventions

DRUG: ACT-539313
DRUG: Placebo

Sponsor

Idorsia Pharmaceuticals Ltd.